Cargando…

Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence

We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, Laura E. J., Tjong, Leonardien K., Rietdijk, Wim J. R., van Gelder, Teun, Koch, Birgit C. P., Versmissen, Jorie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773364/
https://www.ncbi.nlm.nih.gov/pubmed/35052816
http://dx.doi.org/10.3390/biomedicines10010137
_version_ 1784636066479734784
author Peeters, Laura E. J.
Tjong, Leonardien K.
Rietdijk, Wim J. R.
van Gelder, Teun
Koch, Birgit C. P.
Versmissen, Jorie
author_facet Peeters, Laura E. J.
Tjong, Leonardien K.
Rietdijk, Wim J. R.
van Gelder, Teun
Koch, Birgit C. P.
Versmissen, Jorie
author_sort Peeters, Laura E. J.
collection PubMed
description We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc study had all participated in a single-blind randomized controlled trial called RHYME-RCT (Dutch Trial Register, NL6736). Concentrations in blood of several AHDs were assessed in RHYME-RCT to investigate adherence to treatment. This allowed for a comparison of drug exposure to spironolactone and canrenone between males and females. In linear regression models, no statistically significant sex differences (N = 35) in spironolactone (B =−10.23, SE = 7.92, p = 0.206) or canrenone (B = 1.24, SE = 10.96, p = 0.911) concentrations after adjustment for dose and time between sampling and intake were found. Furthermore, no statistically significant differences in non-adherence to spironolactone were found between sexes (N = 54, male 15% vs. female 38%, p = 0.100), but non-adherence to spironolactone was associated with non-adherence to other AHDs (p ≤ 0.001). Spironolactone and canrenone concentrations were not different between males and females with resistant hypertension. Although not statistically significant, females were twice as likely to be non-adherent to spironolactone compared to males, and thereby also more likely to be non-adherent to other AHDs.
format Online
Article
Text
id pubmed-8773364
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87733642022-01-21 Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence Peeters, Laura E. J. Tjong, Leonardien K. Rietdijk, Wim J. R. van Gelder, Teun Koch, Birgit C. P. Versmissen, Jorie Biomedicines Article We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc study had all participated in a single-blind randomized controlled trial called RHYME-RCT (Dutch Trial Register, NL6736). Concentrations in blood of several AHDs were assessed in RHYME-RCT to investigate adherence to treatment. This allowed for a comparison of drug exposure to spironolactone and canrenone between males and females. In linear regression models, no statistically significant sex differences (N = 35) in spironolactone (B =−10.23, SE = 7.92, p = 0.206) or canrenone (B = 1.24, SE = 10.96, p = 0.911) concentrations after adjustment for dose and time between sampling and intake were found. Furthermore, no statistically significant differences in non-adherence to spironolactone were found between sexes (N = 54, male 15% vs. female 38%, p = 0.100), but non-adherence to spironolactone was associated with non-adherence to other AHDs (p ≤ 0.001). Spironolactone and canrenone concentrations were not different between males and females with resistant hypertension. Although not statistically significant, females were twice as likely to be non-adherent to spironolactone compared to males, and thereby also more likely to be non-adherent to other AHDs. MDPI 2022-01-08 /pmc/articles/PMC8773364/ /pubmed/35052816 http://dx.doi.org/10.3390/biomedicines10010137 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peeters, Laura E. J.
Tjong, Leonardien K.
Rietdijk, Wim J. R.
van Gelder, Teun
Koch, Birgit C. P.
Versmissen, Jorie
Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title_full Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title_fullStr Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title_full_unstemmed Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title_short Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
title_sort sex differences in spironolactone and the active metabolite canrenone concentrations and adherence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773364/
https://www.ncbi.nlm.nih.gov/pubmed/35052816
http://dx.doi.org/10.3390/biomedicines10010137
work_keys_str_mv AT peeterslauraej sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence
AT tjongleonardienk sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence
AT rietdijkwimjr sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence
AT vangelderteun sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence
AT kochbirgitcp sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence
AT versmissenjorie sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence